C. Steidl

Integrative genomic analysis identifies unique immune environments associated with immunotherapy response in diffuse large B cell lymphoma

This study identifies unique immune environments in DLBCL associated with response to immunotherapy using an integrative multi-omic approach.

Single cell spatial analysis and biomarker discovery in Hodgkin lymphoma

This study uses spatial imaging to analyze Hodgkin lymphoma tumor microenvironments and identifies new biomarkers related to immune cell interactions and checkpoints.

The spatially resolved tumor microenvironment predicts treatment outcome in relapsed/refractory Hodgkin lymphoma

The paper develops a prognostic model using spatially resolved tumor microenvironment features to predict treatment outcomes in relapsed/refractory Hodgkin lymphoma.

Cooperative super-enhancer inactivation caused by heterozygous loss of CREBBP and KMT2D skews B cell fate decisions and yields T cell-depleted lymphomas

This study shows that combined loss of CREBBP and KMT2D disrupts super-enhancer function in B cells, leading to immune evasion and T cell depletion in lymphomas.

Unmasking the cryptic immunopeptidome of EZH2 mutated diffuse large B-cell lymphomas through combination drug treatment

The paper identifies tumor-specific MHC ligands in EZH2-mutated DLBCLs by combining epigenetic drugs and interferon gamma, expanding the immunopeptidome for immunotherapy targets.

Non-coding NFKBIZ 3' UTR mutations promote cell growth and resistance to targeted therapies in diffuse large B-cell lymphoma

This study identifies non-coding NFKBIZ 3' UTR mutations as drivers of DLBCL growth and resistance to NF-κB-targeted therapies, suggesting their potential as biomarkers.